期刊档案 · Medicine-Internal Medicine
Journal of Lipid and Atherosclerosis
ISSN 2287-2892 · eISSN 2288-2561 · The Korean Society of Lipid and Atherosclerosis · Korea, Republic of
Journal of Lipid and Atherosclerosis 钻石开放获取(无 APC),免版面费,近 24 个月 66 篇文章投稿到接收中位 87 天,2025 年发文 41 篇,Scopus 收录。
研究范围
研究范围与定位
Journal of Lipid and Atherosclerosis 由 The Korean Society of Lipid and Atherosclerosis 出版。按 OpenAlex 近年发文统计,该刊主要发表 Lipoproteins and Cardiovascular Health、Diabetes, Cardiovascular Risks, and Lipoproteins、Cholesterol and Lipid Metabolism 等主题的论文,这 3 个主题约占 44.2%,主导子领域为 Surgery、Cardiology and Cardiovascular Medicine。(根据 OpenAlex 主题统计与中科院分区数据生成)
The Journal of Lipid and Atherosclerosis (JLA), an international and peer-reviewed journal, is the official publication of the Korean Society of Lipid and Atherosclerosis. Its abbreviated title is ‘J Lipid Atheroscler (JLA)’. The JLA is published three times a year (January 25, May 25, and September 25). Aims The JLA aims to advance knowledge in lipid metabolism and atherosclerosis while enhancing understanding of the prevention, management of risk factors, and treatment of cardiovascular diseases. Scope The JLA publishes high-quality basic, translational, and clinical research in lipid metabolism, atherosclerosis, and cardiovascular disease. Topics include lipid disorders, vascular diseases, metabolism, clinical nutrition, and cardiovascular health. The journal also features methodological rounds that provide educational fundamentals and practical insights for researchers. While rooted in the Asian scientific community as the official publication of the Korean Society of Lipid and Atherosclerosis, the JLA is an international journal that actively welcomes submissions from researchers worldwide, fostering global collaboration and advancing scientific knowledge across borders. ·
摘自期刊官网 Aims & Scope
研究方向(LetPub):Medicine-Internal Medicine
主编 Best Practice Research出版商官网
编委会国家分布:中国大陆 2 位(约 3%);主要国家 韩国 34、阿根廷 4、巴西 3、中国 2、美国 2(共 63 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Lipoproteins and Cardiovascular HealthMedicine23.8%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine12.2%
- Cholesterol and Lipid MetabolismMedicine8.3%
- Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology6.5%
- Lipid metabolism and disordersMedicine6.4%
- Cardiovascular Health and Risk FactorsMedicine4.3%
- Acute Myocardial Infarction ResearchMedicine3.9%
- Coronary Interventions and DiagnosticsMedicine3.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》( 2026年3月发布)未收录
该期刊未被此版本分区表收录。
期刊分区表( 2023年12月旧的升级版)未收录
该期刊未被此版本分区表收录。
CiteScore 分区(Scopus,2026 年 6 月版)
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Cardiology and Cardiovascular Medicine | Q1 | 35/409 | 91% |
| Endocrinology, Diabetes and Metabolism | Q1 | 29/250 | 88% |
| Internal Medicine | Q1 | 25/179 | 86% |
Scopus 按 CiteScore 在每个学科内为期刊排名,百分位 75 及以上为 Q1,每 25 为一档;与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
PMCPubMed出版商官网
其他:Google Scholar、Crossref、KoreaMed、KoreaMed Synapse、KoMCI
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 10.2LetPub ·
- SJR 2026-06
- 1.84LetPub ·
- SNIP 2026-06
- 2.23LetPub ·
- h-index
- 31OpenAlex ·
- i10-index
- 98OpenAlex ·
- 两年平均被引
- 4.05OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 481 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 41 | 41 | 863 |
| 2025 | 41 | 41 | 1,088 |
| 2024 | 32 | 32 | 853 |
| 2023 | 29 | 29 | 553 |
| 2022 | 27 | 27 | 466 |
| 2021 | 26 | 26 | 253 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
87 天投稿到接收中位数 · P25–P75 54 天 – 105 天
- 接收到上线
- 中位数 58 天(66 篇)
- 投稿到上线
- 中位数 153 天
- 样本
- 66 篇有投稿与接收日期的文章(窗口内共 70 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 12 WeeksLetPub ·
- 投稿到发表(期刊自报)
- 约 12 周DOAJ ·
- 评审方式
- 同行评审(未说明方式)DOAJ
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
所有文章开放获取,且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY-NC | |
| LetPub | 无文章处理费 | 无 | — | |
| 出版商官网 | 有,金额未公布 | — | — |
其他费用与减免(作者指南)
- 其他费用
- 无其他费用
- 版面费
- 无版面费
- 投稿费
- 无投稿费
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
接收的文章类型7 种
- brief reportsThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
- editorialManuscripts are examined by the editorial board and re-evaluated by two or three expert reviewers assigned by the board. Another reviewer can be assigned if nee…未说明篇幅
- editorialsThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
- letters to editorsThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
- methodology roundsThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
- original articlesThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
- review articlesThe JLA accepts and publishes original articles, review articles, brief reports, editorials, methodology rounds, and letters to editors.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、同行评审、查重、预印本
- AI 使用 Use of artificial intelligence (AI)-assisted technologies
JLA follows the recommendations of the International Committee of Medical Journal Editors (ICMJE) regarding the use of artificial intelligence (AI)-assisted technologies in scientific publishing. AI tools, including chatbots and other generative AI systems, must not be listed as authors or cited as authors. Authors remain fully responsible for the accuracy, integrity, originality, and final conten…
原文 ↗出版商官网 ·- 作者资格 Journal policies on authorship and contributorship
ICMJE建议作者资格基于以下4项标准:对工作的构思或设计有实质性贡献,或为工作获取、分析或解释数据;起草工作或对其进行重要的学术内容修改;对拟发表版本进行最终批准;同意对工作的所有方面负责,确保与工作任何部分的准确性或诚信相关的问题得到适当调查和解决。 模型中文摘要
The ICMJE recommends that authorship be based on the following 4 criteria: 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2) Drafting the work or revising it critically for important intellectual content; AND 3) Final approval of the version to be published; AND 4) Agreement to be accountable for all a…
原文 ↗出版商官网 ·- 利益冲突 Journal policies on conflicts of interest/competing interests
所有作者必须披露可能影响或被认为影响稿件所报告工作的任何财务或非财务竞争利益,通讯作者负责在投稿时提交所有作者的披露信息,所有资金来源必须明确说明,并描述资助者在研究设计、数据收集、分析、解释、稿件准备及决定投稿发表中的作用;如无竞争利益,稿件应声明:“作者声明不存在竞争利益。” 模型中文摘要
All authors must disclose any financial or non-financial competing interests that could influence, or be perceived to influence, the work reported in the manuscript. The corresponding author is responsible for submitting disclosure information for all authors at the time of submission. All sources of funding must be stated explicitly, and the role of any sponsor in study design, data collection, a…
原文 ↗出版商官网 ·- 数据可用性 Journal policies on data sharing and reproducibility
该期刊支持数据共享和透明度以提高已发表研究的准确性和可重复性,原创研究文章应包含数据可用性声明,说明原始数据、分析数据、分析代码或研究材料是公开可用、可按合理请求提供,还是因法律、伦理或隐私限制而不可用;如数据公开可用,应提供存储库名称、DOI或URL,并鼓励作者在稿件被接受后将相关数据存入公共存储库。 模型中文摘要
JLA supports data sharing and transparency to improve the accuracy and reproducibility of published research. Original research articles should include a Data Availability Statement describing whether the raw data, analysis data, analytic code, or study materials are publicly available, available on reasonable request, or unavailable because of legal, ethical, or privacy restrictions. If data are …
原文 ↗出版商官网 ·- 出版伦理
该期刊在处理投诉、申诉以及研究或出版不端行为的指控时遵循出版伦理委员会(COPE)的相关指导。 模型中文摘要
JLA follows relevant COPE guidance in handling complaints, appeals, and allegations of research or publication misconduct.
原文 ↗出版商官网 ·- 许可与版权
所有已发表论文均成为韩国脂质与动脉粥样硬化学会的永久财产,文章发表后所有版权转让给韩国脂质与动脉粥样硬化学会。 模型中文摘要
All published papers have become the permanent property of the Korean Society of Lipid and Atherosclerosis. Upon publication of the articles, all the copyrights are transferred to the Korean Society of Lipid and Atherosclerosis.
原文 ↗出版商官网 ·- 同行评审 Editorial and Peer Review Process
稿件由编辑委员会审查并由委员会指定的两至三名专家审稿人重新评估,必要时可增加审稿人;该期刊采用双盲审稿,即审稿人和作者身份在整个审稿过程中相互保密,作者需确保稿件准备方式不泄露其身份;通常在收到稿件后4周内作出初步决定,审稿人意见通过电子邮件发送给通讯作者。 模型中文摘要
Manuscripts are examined by the editorial board and re-evaluated by two or three expert reviewers assigned by the board. Another reviewer can be assigned if needed. JLA uses double-blind review, which means that both the reviewer and author identities are concealed from the reviewers, and vice versa, throughout the review process. To facilitate this, authors need to ensure that their manuscripts a…
原文 ↗出版商官网 ·- 查重 Plagiarism and duplicate publication
抄袭被定义为未经适当署名使用先前发表的材料,在同行评审之前,所有投稿稿件均由主编使用iThenticate进行抄袭筛查;如在发表前或发表后的任何阶段发现抄袭或实质性文本重叠,该期刊将根据出版伦理委员会(COPE)的相关指导采取适当的编辑行动。 模型中文摘要
Plagiarism is defined as the use of previously published material without appropriate attribution. Prior to peer review, all submitted manuscripts are screened for plagiarism by the Editor-in-Chief using iThenticate. If plagiarism or substantial textual overlap is identified at any stage before or after publication, JLA will take appropriate editorial action in accordance with the relevant guidanc…
原文 ↗出版商官网 ·- 预印本 Preprint policy (Posted on March 2, 2023)
A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer-reviewed scholarly journal. JLA allows authors to submit a manuscript that have been posted on preprint platform to the journal. It is not treated as duplicate submission or duplicate publication. JLA recommend authors to disclose it with only single DOI during the submission proc…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- The Korean Society of Lipid and Atherosclerosis
- 出版国家或地区
- Korea, Republic of
- 出版语言
- English, Korean
- ISSN
- 2287-2892
- 电子版 ISSN
- 2288-2561
- 学会 / 主办单位
- Korean Society of Lipid and Atherosclerosis
- 官网最新一期
- Volume 15, Issue 2(2026 年 5 月)
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
常见问题
关于 Journal of Lipid and Atherosclerosis 的常见问题
Journal of Lipid and Atherosclerosis 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)66 篇已发表文章登记的日期,投稿到接收的中位数为 87 天(四分位 54–105 天);投稿社区反馈的平均审稿速度为约 12 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Journal of Lipid and Atherosclerosis 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 63 位编委中,中国大陆 2 位(约 3%);人数最多的国家是 韩国(34 位)、阿根廷(4 位)、巴西(3 位)。统计按编委会页面列出的机构国家计,仅供参考。
Journal of Lipid and Atherosclerosis 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Journal of Lipid and Atherosclerosis 被 Scopus、DOAJ 收录。期刊官网自述还被 PMC、PubMed 收录,该清单未与各数据库逐一核对。
Journal of Lipid and Atherosclerosis 是开放获取期刊吗?版面费多少?
Journal of Lipid and Atherosclerosis 为钻石开放获取(无 APC)。不收取文章处理费。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。